NIFE (AIO-YMO HEP-0315)
The German NIFE trial gave liposomal irinotecan with fluorouracil as a first treatment for bile duct and gallbladder cancer alongside a standard gemcitabine and cisplatin arm, each judged on its own by the share of patients free of progression at four months. It completed with 93 patients.
Overview
NIFE (NCT03044587) was an interventional, prospective, randomised, open-label two-sided phase 2 designed with a Simon two-stage design in each arm: nal-IRI 80 mg/m², fluorouracil 2,400 mg/m² and leucovorin 400 mg/m² every 14 days (arm A) versus cisplatin 25 mg/m² and gemcitabine 1,000 mg/m² days 1 and 8 every 21 days (arm B), analysed unconnected. Randomisation was stratified by tumour site (intrahepatic versus extrahepatic biliary tract), stage, age, sex and performance status. The primary endpoint was the progression-free survival rate at four months in each arm, with overall progression-free survival, three-year survival, disease control at two months, safety and quality of life as secondary endpoints. The registry records 93 patients enrolled at German sites, primary completion in January 2022 and study completion in January 2025. A primary results paper was not found in Europe PMC in September 2026; only the protocol is indexed. It sits between NIFTY (positive, second line) and NALIRICC (negative, second line) in the liposomal irinotecan story.
Similar pages
not linked directly; found by shared links- TrialNAPOLI-2: Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Biliary Cancer
Shares Liposomal irinotecan, Leucovorin (folinic acid), Fluorouracil (5-FU), Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups).
- TrialLiposomal Irinotecan Plus 5-FU/LV and Sintilimab With Sequential SBRT for Locally Advanced Biliary Tract Cancer
Shares Liposomal irinotecan, Leucovorin (folinic acid), Fluorouracil (5-FU), Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups).
- TrialIvonescimab in Combination With Liposomal Irinotecan and 5-FU/LV in Potentially Resectable Biliary Tract Malignancies
Shares Liposomal irinotecan, Fluorouracil (5-FU), Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types).
- TrialA Randomized, Two-cohort, Prospective Phase II Clinical Study of the Second-line Treatment of Advanced Biliary System Tumors With Liposomal Irinotecan (II) Combination Regimen
Shares Liposomal irinotecan, Fluorouracil (5-FU), Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types).
- TrialNALIRICC (AIO)
Shares Liposomal irinotecan, Leucovorin (folinic acid), Fluorouracil (5-FU), Biliary tract cancer (all types).
- TrialCadonilimab Combined With Liposomal Irinotecan Plus Leucovorin and Fluorouracil for Advanced Cholangiocarcinoma
Shares Liposomal irinotecan, Leucovorin (folinic acid), Fluorouracil (5-FU), Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups).
- TrialCPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors
Shares Fluorouracil (5-FU), Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups), Biliary tract cancer (all types), Biliary tract cancer (cholangiocarcinoma).
- TrialNIFTY
Shares Liposomal irinotecan, Leucovorin (folinic acid), Fluorouracil (5-FU), Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups).